Akebia Therapeutics (NASDAQ:AKBA – Get Rating) and Alterity Therapeutics (NASDAQ:ATHE – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Valuation & Earnings This table compares Akebia Therapeutics and […]
Markets
Needham analyst Chad Messer maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $134.00. The company’s shares closed last Tuesday at $26.88, close to its 52-week low of $23.90.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 47.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $47.14 average price target, which is a 66.0% upside from current levels. In a report released yesterday, Credit Suisse also initiated coverage with a Buy rating on the stock with a $45.00 price target.